Welcome to the Podiatry Arena forums

You are currently viewing our podiatry forum as a guest which gives you limited access to view all podiatry discussions and access our other features. By joining our free global community of Podiatrists and other interested foot health care professionals you will have access to post podiatry topics (answer and ask questions), communicate privately with other members, upload content, view attachments, receive a weekly email update of new discussions, access other special features. Registered users do not get displayed the advertisements in posted messages. Registration is fast, simple and absolutely free so please, join our global Podiatry community today!

  1. Have you considered the Clinical Biomechanics Boot Camp Online, for taking it to the next level? See here for more.
    Dismiss Notice
Dismiss Notice
Have you considered the Clinical Biomechanics Boot Camp Online, for taking it to the next level? See here for more.
Dismiss Notice
Have you liked us on Facebook to get our updates? Please do. Click here for our Facebook page.
Dismiss Notice
Do you get the weekly newsletter that Podiatry Arena sends out to update everybody? If not, click here to organise this.

P-3058 for onychomycosis

Discussion in 'General Issues and Discussion Forum' started by NewsBot, Sep 14, 2015.

  1. NewsBot

    NewsBot The Admin that posts the news.

    Articles:
    1

    Members do not see these Ads. Sign Up.
    These two clinical trials were just registered:
    Clinical Trial on Onychomycosis With P-3058 Nail Solution in Pediatric Population
    Study to Evaluate the Efficacy and Safety of P-3058 10% Nail Solution in the Treatment of Toenail Onychomycosis
     
  2. NewsBot

    NewsBot The Admin that posts the news.

    Articles:
    1
    An innovative terbinafine transungual solution (P-3058): Dose finding investigation on clinical benefit in patients affected by mild-to-moderate toe onychomycosis
    JAAD; April 2013Volume 68, Issue 4, Supplement 1, Page AB102
    Matilde Iorizzo, MD, dermatology private practice, Bellinzona, Switzerland; Federico Mailland, MD, Polichem SA, Lugano, Switzerland; Gustavo Arraiz, ScD, Sintesi Research s.r.l., Milan, Italy; Linda Frisenda, ScD, Polichem SA, Lugano, Switzerland; Maurizio Caserini, MD, Polichem SA, Lugano, Switzerland
     
Loading...

Share This Page